Merck, Inc.
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
- Conditions
- Adenocarcinoma in SituPapillomavirus InfectionsVaginal NeoplasmsCondylomata AcuminataVulvar NeoplasmsUterine Cervical Neoplasms
- Interventions
- Biological: 9vHPV vaccine
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 201
- Registration Number
- NCT03546842
- Locations
- 🇻🇳
National Institute of Hygiene and Epidemiology ( Site 0001), Hanoi, Vietnam
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: V114Biological: Prevnar 13™Biological: PNEUMOVAX™23
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1515
- Registration Number
- NCT03547167
- Locations
- 🇨🇦
Dynamik Research ( Site 0095), Pointe-Claire, Quebec, Canada
🇺🇸Evanston Premier Healthcare & Research, LLC. ( Site 0012), Evanston, Illinois, United States
🇨🇦Q & T Research Sherbrooke Inc. ( Site 0097), Sherbrooke, Quebec, Canada
Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)
- Conditions
- Hepatitis C
- Interventions
- Biological: PEG-IntronBiological: Interferon Alfa-2B
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1224
- Registration Number
- NCT03537274
Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
- Conditions
- Respiratory Tract InfectionRespiratory Syncytial Virus
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 183
- Registration Number
- NCT03524118
- Locations
- 🇿🇦
Chris Hani Baragwanath Academic Hospital ( Site 0262), Johannesburg, Gauteng, South Africa
🇺🇸Next Phase Research Alliance, LLC ( Site 0075), Homestead, Florida, United States
🇺🇸Cotton-O'Neil Clinical Research Center PediatricCare ( Site 0081), Topeka, Kansas, United States
Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).
- Conditions
- Neuromuscular Blockade
- Interventions
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 99
- Registration Number
- NCT03519854
Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042)
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT03519867
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
- Conditions
- Advanced Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 318
- Registration Number
- NCT03516981
- Locations
- 🇵🇱
Dolnoslaskie Centrum Onkologii. ( Site 0993), Wroclaw, Dolnoslaskie, Poland
🇨🇦Jewish General Hospital ( Site 0307), Montreal, Quebec, Canada
🇺🇸University of California Davis Comprehensive Cancer Center ( Site 0137), Sacramento, California, United States
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 492
- Registration Number
- NCT03515837
- Locations
- 🇨🇳
Tangdu Hospital ( Site 0708), XI An, Shanxi, China
🇨🇳Southwest Hospital, The Third Military Medical University ( Site 0725), Chongqing, Chongqing, China
🇨🇳Henan Cancer Hospital ( Site 0711), Zhengzhou, Henan, China
Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)
- Conditions
- NeoplasmsHead and Neck NeoplasmsColorectal Neoplasms
- Interventions
- Biological: MK-1697
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT03515824
- Locations
- 🇦🇺
Scientia Clinical Research ( Site 0100), Randwick, New South Wales, Australia
🇭🇰Queen Mary Hospital ( Site 0200), Hong Kong, Hong Kong
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
- Conditions
- Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 766
- Registration Number
- NCT03493542
- Locations
- 🇨🇳
Yangchun Center For Disease Prevention And Control ( Site 0003), Yangchun, Guangdong, China